Related Experiment Video
Updated: Feb 21, 2026
04:56
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
1.3K
A safety evaluation of evolocumab
1a Division of Cardiovascular Health and Disease , University of Cincinnati & Sterling Research Group LTD , Cincinnati , OH , USA.
Expert Opinion on Drug Safety
|October 10, 2017
Summary
Evolocumab, a PCSK9 inhibitor, demonstrates remarkable safety and efficacy in lowering LDL-C, offering a significant advance in lipid therapy and cardiovascular disease prevention.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Lipidology
Background:
- Evolocumab is a novel proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, representing a significant advancement in lipid-lowering therapy.
- PCSK9 inhibitors offer unprecedented efficacy in reducing low-density lipoprotein cholesterol (LDL-C) levels, surpassing previous treatments.
- This review focuses on the safety profile of evolocumab, evaluating various potential adverse effects.
Purpose of the Study:
- To comprehensively review the safety of evolocumab, a PCSK9 inhibitor.
- To assess the efficacy of evolocumab in lowering LDL-C, with and without other lipid-lowering therapies.
- To evaluate the long-term safety data from clinical trials, including extension studies and outcomes trials like FOURIER.
Main Methods:
- Review of Phase II and III clinical trials of evolocumab.
- Analysis of open-label extension studies for long-term safety data.
- Inclusion of data from the FOURIER outcomes trial.
Main Results:
- Evolocumab consistently demonstrates high LDL-C lowering efficacy.
- The safety profile of evolocumab is remarkable and encouraging, with specific attention to cognitive function, diabetes risk, and other potential adverse effects.
- LDL-C levels achieved with evolocumab are lower than previously attainable.
Conclusions:
- Evolocumab offers a highly effective and generally safe option for LDL-C reduction.
- PCSK9 inhibitors, including evolocumab, herald a new era in lipid management and cardiovascular disease prevention.
- The established efficacy and safety profile of evolocumab provide a valuable new tool for clinical practice.
Related Concept Videos
01:19Pharmacovigilance
1.8K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.8K
01:13Bioequivalence studies: Biowaivers
306
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
306
01:12Relative Risk
2.3K
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
2.3K
01:30Acute Coronary Syndrome III: Diagnostic Studies
316
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
316
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
491
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
491